



- (51) **International Patent Classification:**
G16B 20/20 (2019.01) *G16B 40/20* (2019.01)
- (21) **International Application Number:**
PCT/US2024/039936
- (22) **International Filing Date:**
26 July 2024 (26.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/515,801 26 July 2023 (26.07.2023) US
- (71) **Applicant: THE BROAD INSTITUTE, INC.** [US/US];
415 Main Street, Cambridge, MA 02142 (US).
- (72) **Inventors: ADALSTEINSSON, Viktor A.;** c/o The Broad Institute, Inc., 415 Main Street, Cambridge, Massachusetts 02142 (US). **BLEWETT, Timothy David;** C/o The Broad Institute, Inc., 415 Main Street, Cambridge, Massachusetts 02142 (US). **LIU, Ruolin;** c/o The Broad Institute, Inc., 415 Main Street, Cambridge, Massachusetts 02142 (US).
- (74) **Agent: WALSH, Patrick et al.;** FIG.1 Patents, 116 W. Pacific Avenue, Suite 200, Spokane, WA 99201 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) **Title:** DYNAMIC MINIMAL RESIDUAL DISEASE DETECTION




FIG. 1

(57) **Abstract:** The present disclosure relates to systems and methods for detecting circulating tumor DNA (ctDNA) and minimal residual disease in a patient sample. Aspects of the present disclosure relate to use of a classification module to assess whether a patient sample comprises ctDNA and minimal residual disease based, in part, on patient-specific inputs. The present disclosure is also related, at least in part, to a determination of whether a patient has cancer based on an output of the classification module.

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*